Masitinib Triples ALS Five-Year Survival Rates in Landmark Trial Data
New phase 2b/3 trial data shows masitinib plus riluzole achieved 42.3% five-year ALS survival versus a 24% registry benchmark.
Summary
A new analysis from AB Science's phase 2b/3 trial shows that ALS patients treated with masitinib combined with riluzole achieved a five-year survival rate of 42.3% from symptom onset — far above the 7–27.8% range seen in standard registry data. Among patients who retained some functional ability at the start of treatment, survival climbed to 52.9%. Nearly half of long-term survivors maintained quality of life without mechanical ventilation, feeding tubes, or wheelchair dependence. The findings will be presented at the ENCALS annual meeting in Madrid on June 25, 2026. Researchers also identified a potential biomarker to predict who responds best to masitinib, though confirmation is still needed. These results suggest masitinib could meaningfully extend survival and functional independence in ALS patients.
Detailed Summary
Amyotrophic lateral sclerosis remains one of the most devastating and rapidly fatal neurological diseases, with most patients surviving only two to five years after diagnosis. Effective treatments are critically lacking, making any signal of substantially improved long-term survival highly significant for patients, clinicians, and researchers alike.
AB Science's phase 2b/3 AB10015 trial evaluated masitinib — a tyrosine kinase inhibitor with anti-neuroinflammatory properties — added to the standard drug riluzole. The latest long-term analysis reports a five-year survival rate of 42.3% from symptom onset among treated patients. This rises to 52.9% in those who had not yet lost complete functionality when they started treatment, suggesting early intervention may be especially important.
Perhaps equally meaningful is the quality-of-life dimension: 49% of long-term survivors reportedly maintained independence from major mechanical interventions — permanent ventilation, tracheostomy, gastrostomy, and wheelchair use. Survival statistics alone rarely capture how ALS erodes daily life, so this functional independence data adds significant weight to the findings.
The company contrasts these results against registry benchmarks showing five-year survival ranging from just 7% to 27.8%, with a weighted average near 24%. If confirmed, masitinib could represent a step-change improvement over current standard of care. Researchers also flagged a newly identified biomarker that may predict which patients are most likely to respond, potentially enabling precision prescribing — though additional validation is required before clinical use.
Important caveats apply. These results are company-reported from a single trial and have not yet been peer-reviewed or published in full. The comparison to registry benchmarks, rather than a randomized control arm in the same study, introduces potential confounding. Independent replication and regulatory scrutiny will be essential before masitinib enters routine ALS care.
Key Findings
- Masitinib plus riluzole achieved 42.3% five-year ALS survival versus a ~24% registry weighted average.
- Patients with retained baseline functionality had even higher five-year survival at 52.9%.
- 49% of long-term survivors maintained independence from ventilators, feeding tubes, and wheelchairs.
- A new biomarker may identify masitinib responders, enabling more targeted treatment selection.
- Findings are company-reported and await independent peer review and regulatory evaluation.
Methodology
This is a news report summarizing company-issued data from a phase 2b/3 clinical trial (AB10015) by AB Science. The evidence basis is a long-term survival analysis accepted for poster presentation at ENCALS 2026; full peer-reviewed publication has not been confirmed. Source is Longevity.Technology, a credible longevity-focused outlet, though the underlying data originates from the drug developer.
Study Limitations
Results are company-reported and not yet independently peer-reviewed, introducing potential bias. Survival comparisons rely on historical registry benchmarks rather than a concurrent randomized control group, which limits causal interpretation. The newly identified biomarker requires confirmatory evidence before clinical application.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.